Life Technologies Supports Global Effort to Help Accelerate Emergency Screening of Avian Influenza (H7N9) Virus

    Life Technologies Supports Global Effort to Help Accelerate Emergency
                  Screening of Avian Influenza (H7N9) Virus

Company's instruments FDA-cleared under Emergency Use Authorization

PR Newswire

CARLSBAD, Calif., April 26, 2013

CARLSBAD, Calif., April 26, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced that its Applied Biosystems® 7500 Fast Dx
Real-Time PCR instrument is the sole platform cleared for use under the
Centers for Disease Control and Prevention (CDC) protocol created for
emergency screenings of patients suspected of harbouring the Avian influenza
(H7N9) virus, which to date has led to 23 deaths in China and Taiwan.

Cleared under the U.S. Food and Drug Administration's (FDA) Emergency Use
Authorization (EUA), the 7500 Fast Dx Real-Time PCR instrument, in addition to
Life's SuperScript III One-Step qRT-PCR reagent kit, is intended to be used
with the CDC's human influenza virus assay to quickly monitor the spread of
the pathogen and thwart a potential pandemic. To support this global need,
Life Technologies is increasing production of its reagents and shipping them
to labs around the world.

Life Technologies has a strong history of working with the CDC, the World
Health Organization (WHO) and public health labs to combat virus outbreaks:

  o2009 – Life Technologies formed a special 24-hour-a-day task force to
    respond to global requests for assistance with the H1N1 outbreak.
  o2011 – Life Technologies developed a custom assay to accurately detect
    theE. colibacterium that spread through Europe. The assay was developed
    after company researchers, using samples supplied by scientists at
    University Hospital Munster, completed the DNA sequencing and analysis
    work on the deadlyE. colistrain using the Ion PGM™ Sequencer. 
  o2012 – Life Technologies established the Global Influenza Network, a
    partnership of scientists at a number of the world's leading government
    public health organizations, veterinary agencies and research institutes
    who collaborate in an effort to increase the speed and efficiency of
    influenza monitoring and vaccine development.
  oToday – Life Technologies' Ion PGM™ Sequencer is being used to
    characterize the genetic sequence of the virus and to determine if it can
    be transmitted from human to human.

"We have learned through our past experiences that a strong surveillance
program is crucial in times like these," said Dan Didier, Public Health
Director for Life Technologies. "We are working continually with our partners
around the globe on improving our capabilities, particularly when it comes to
developing rapid detection kits."

Cases of the H7N9 virus have been reported out of China and Taiwan only.
First cases of the human virus were confirmed in March with more than 100

SuperScript III One-Step qRT-PCR kit is for research use only; not intended
for diagnostic purposes.

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Media Contact:
Patty Zamora

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.